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Current therapies to heal peptic ulcers and eradicate Helicobacterpylori gener-
ally rely on a combination of antibacterial agents and anti-secretory drugs. The
major factors affecting the outcome ofthese eradication therapies are the selec-
tion of antibiotic(s), daily dose, the dosage regimen(s) selected and duration of
dosing and patient non-compliance due to side effects ornumber ortablets to be
taken. Future therapies will seek to maximize effectiveness through taking
account ofthese factors.
The only new drug to be introduced in recent years uniquely for the eradication
of H. pylori is ranitidine bismuth citrate, which when combined with a single
antibiotic (clarithromycin) or two antibiotics has been shown to be highly effec-
tive (even against H. pylori "resistant" to clarithromycin, treated with the sim-
ple dual therapy).
Awareness of the increasing resistance ofHelicobacterpylori to antibiotics, particu-
larly the nitroimidazoles and macrolides, acquired either during or before therapy is
becoming a significant concern. Thus, there is a need for therapies that either prevent
acquisition of resistance or are effective against organisms already resistant. At present
there is no suitably-effective single drug available for use as monotherapy. It is also known
that single or multiple antibiotics are only capable oferadicating H. pylori by enhanced or
potentiated efficacy due to the suppression of gastric acid or by addition of bismuth. For
this reason, the concept of monotherapy against H. pylori is not possible with currently-
available drugs.
Other approaches in therapy for H. pylori infection include a "therapeutic" vaccine
(immunotherapy) in which the IgA-mediated mucosal immune response is boosted to
cause elimination of the organism. Issues relating to the success of this approach involve
the choice ofH. pylori antigen(s), a suitable adjuvant such as a soluble protein or an atten-
uated live organism, and the nature ofthe vaccination programm. Another novel approach
being pursued involves the use of "anti-adhesive" agents to prevent or remove H. pylori
adherence to the gastric mucosa (or mucus). This may have an advantage of providing a
selective agent which may prevent gastritis due to the adherent bacteria, but may have to
be used as part ofcombination eradication therapy.
Further into the future, more "rational" therapies are likely to be developed based on
greater knowledge of the organism (genome sequence/metabolic pathways) and its eco-
logical environment. However, the concepts ofmonotherapy and vaccines are major ther-
apeutic challenges and agents for the clinic from on-going basic research are unlikely to
be seen over the next five years due to the long duration ofthe drug development process.
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HELICOBACTER PYLORI - THE ORGANISM
H. pylori has evolved over the millennia to survive in a specialized micro-environ-
ment within the human upper gastrointestinal tract, where it is found closely associated
with gastric epithelium. In addition to the stomach, the organism can also be found on
metaplastic gastric epithelium in the duodenum and on ectopic gastric mucosa at other
sites. Within the stomach, H. pylori preferentially inhabits the gastric antrum although
bacteria may also be found in the fundus. Forexample, changes in intragastric distribution
of H. pylori have been noted during treatment with omeprazole [1, 2]. The bacteria are
often found around intracellularjunctions and adhering to epithelial cell membranes [3],
and it has been reported that H. pylori may occasionally penetrate cells [4], although this
is controversial.
As with other pathogens, an understanding of the factors allowing colonization and
subsequent pathogenicity within the host will enable new therapeutic approaches to be
developed. The virulence factors which enableH. pylori to colonize and subsequently per-
sist or flourish within the host include its motility, adaptive enzymes, and the ability to
adhere togastric epithelium. Certain enzymes and toxins may also play arole in the patho-
genesis ofvarious diseases, forexample, urease, phospholipases and cytotoxins. H. pylori
is well-adapted formotility in gastric mucus [5] being curved or spiral, and having two to
six polar, sheathed flagella, enabling rapid passage through both gastricjuice and gastric
mucus [6]. The organism is able to survive in gastricjuice prior to penetrating the protec-
tive layer of mucus over the gastric epithelium by means of its abundant urease, generat-
ing bicarbonate and ammonium ions around theorganism to form a protective micro-envi-
ronment. In addition to its role as a survival factor, urease activity may be associated with
tissuedamage due to theproduction ofammonia [7-10].All Helicobacterspecies produce
large amounts of catalase which protects the bacteria from toxic metabolites associated
with lysis ofneutrophils [5].
Selective colonization of gastric, mucus-secreting, epithelial cells by H. pylori is
facilitated by its ability to attach to specific phospholipids and glycoproteins within the
gastric mucosa. In addition, in persons with blood group0, the Lewis B blood group anti-
gens mediate attachment of the organism to the mucous cells [11]. Other putative recep-
tors for H. pylori binding are extracellular matrix components, such as laminin,
fibronectin, collagen types I, IV and V, vitronectin, and heparan sulphate [12-15].
Adhesion of H. pylori at contact sites on gastric epithelium has been categorized as adhe-
sion pedestals, indentation sites, or abutment adhesions although gastric cell injury occurs
irrespective of the morphologic type of attachment [16]. Enzymes from H. pylori, for
example, urease, phospholipases A2 and C, and proteases may be responsible for subse-
quent damage.
Study of the molecular mechanisms by which H. pylori causes disease suggests that
isolates of H. pylori can be divided into two major types. Type I bacteria express a vac-
uolating cytotoxin (VacA) and a cytotoxin-associated antigen (CagA). Type II bacteria
express neitherVacA norCagA. Duodenal ulcerpatients are almostinvariably infected by
Type I H. pylori [17-19]. The vacuolating toxin in cytotoxic strains of H. pylori induces
vacuoles in epithelial cells which results in cell death. The gene for the cytotoxin protein
(VacA), whilst present in all strains of H. pylori, produces an active cytotoxin in only
about 50-60 percent of isolates in vitro [19-21].
Itappears therefore thatpepticulceration, andpossibly gastric cancer, may resultonly
from infection by strains ofH. pyloriproducing bothVacA and CagA. In tissue culture of
gastric epithelial cells, these strains induce secretion of interleukin-8 [22] which may
account for the relationship between severity of disease (i.e., inflammation and subse-
quent ulceration) and presence ofCagA-, VacA-positive bacteria.
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ISSUES FACING ERADICATION OF H. PYLORI
The association between infection by H. pylori and peptic ulcerdisease has been well
recognized over recent years, and approximately 95 percent of patients with duodenal
ulcer and up to 90 percent of those with gastric ulcer are likely to be infected [23]. The
management of peptic ulcer disease has undergone a remarkable evolution over the past
ten years with the recognition that eradication ofH. pylori markedly reduces ulcer recur-
rence and thus diminishes the need for continuous anti-secretory therapy in most patients
[24-26]. However, there is considerable confusion at present concerning appropriate diag-
nostic procedures and therapeutic options. This latter aspect has arisen due to the inabili-
ty of monotherapy with existing antibiotics to eradicate the organism in most patients.
Eradication regimens are becoming increasingly "added-on" to ulcer-healing therapies in
which antibiotics are added to anti-secretory agents. The early absence ofwell-controlled
clinical trials has resulted in a wide array ofproposed dual, triple and even quadruple ther-
apy regimens, many of which have not been adequately tested.
The last decade has seen a large number of "eradication studies," although many of
these have been published only as abstracts or without adequate details to evaluate their
merits. A number of reviews of these data have been published [27-34] which allows the
following general observations. Early studies were dominated by therapy with a bismuth
salt, often for four weeks, plus two antibiotics for the first week or two. Combinations of
colloidal bismuth subcitrate with metronidazole and tetracycline have consistently pro-
vided high eradication rates of over 90 percent [35, 36]. Unfortunately, these triple thera-
pies are often associated with poor patient compliance due to complex dosing schedules
with large number oftablets [37], frequent side-effects [30, 38], and resistance to metron-
idazole [39].
Such limitations led to investigators studying two week, dual therapy options, of
which the most widely reported has been omeprazole plus amoxycillin. Eradication rates
with this regimen have ranged from 0 to 90 percent, with pooled data suggesting an aver-
age rate ofabout 60 percent [33]. Interest in this combination has declined as recent prop-
erly-controlled trials have shown low eradication rates [40-42]. Effort subsequently
focused on the novel macrolide clarithromycin as the antibiotic of choice in dual therapy
regimens, with pooled eradication rates of about 66 percent reported when given in com-
bination with omeprazole [33]. However, current research trends show a revived interest
in short duration (seven day) triple therapies based on proton pump inhibitors plus two
antibiotics, with pooled eradication rates of about 85 percent [33].
During the next few years it is likely that existing and new combination therapies will
be refined and defined through randomized, double-blind clinical trials of sufficient size
to determine optimal therapeutic regimens.
Increasing consideration is being given to developing agents or therapies to eradicate
H. pylori in asymptomatic carriers of the organism in addition to patients with peptic
ulcer, since H. pylori is now accepted as a risk factor in the development ofgastric carci-
noma [43]. Such new therapies may need to work without the need for acid-suppression.
These new agents may represent the "magic bullet" against H. pylori, but they are unlike-
ly to be available this decade.
FACTORS AFFECTING ERADICATION
Drug-related factors such as daily dose, dosing frequency, duration of therapy, pre-
treatment with certain agents, administration before or after food, and antibacterial poten-
cy have major bearings on the efficacy of any eradication regimen. Also patient-related
factors such as disease state, concurrent illness, adverse events, smoking, ethnic origin,
and socio-economic status have also been suggested as being important. The impact of
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patient non-compliance during therapy with short-duration eradication regimens may be
critical to success, but has yet to be evaluated. However, much discussion has been given
over recent years to organism-related factors. These have included organism sub-types,
route of transmission, location within the stomach and gastro-intestinal tract, morpholog-
ical variants, virulence factors, pathogenic mechanisms, resistance mechanisms, and
response to environmental factors.
While modification of drug dose, dosing frequency and duration of therapy of each
component of an eradication regimen may improve efficacy, there are many other factors
which may affect the outcome. For example, the distribution of H. pylori in the stomach
(antrum, fundus, corpus) and at sites of gastric metaplasia in the duodenum may vary
between duodenal and gastric ulcer disease. Moreover, the ability of any antibiotic to
reach and to kill the organism depends on various physico-chemical and metabolic con-
siderations, especially whether topical or systemic activity is needed. Hence, differences
in the location, histology, pH, and other physico-chemical factors of the micro-environ-
ment in the vicinity of the organism couldfead to differences in eradication.
Optimization and standardization ofclinical trial design will be particularly important
in advancing our understanding of the relative merits of different eradication therapies.
Attention has to be given to appropriate comparator or control treatments administered in
a randomized and blinded fashion. Analysis of results should be based on carefully
defined observed or intent-to-treat patient populations, rather than per protocol analysis
which may give misleadingly high eradication results. Much of the existing literature is
confused about which population the analyses are based upon.
It is apparent that although optimisation ofcurrent therapeutic strategies may lead to
greater H. pylori eradication rates and lower ulcer recurrence rates, such combination ther-
apies are not ideal. More rational research to understand the organism, its environment,
and its relationship to gastrointestinal disease is likely to facilitate the development of a
safe and effective monotherapy.
FUTURE APPROACHES TO ERADICATION OF H. PYLORI INFECTION
Potential advances in the therapy ofH. pylori-related disease may come from a num-
ber of alternative approaches. A better understanding of how the infection is transmitted
may provide simple methods ofprevention. It is also clear that there are host factors that
determine individual susceptibility to disease, but this has received little attention to date.
Publications and patents for various novel therapies aimed at eradicating infection are now
emerging. Thus, anti-adhesive agents, novel anti-microbial agents, certain dietary factors,
bacteriocins, urease inhibition/bicarbonate removal, aggressive "topical" therapy,
colostral antibodies and vaccines are all attracting interest. Although it is difficult to assess
which ofthese approaches will be the most effective, most interest at conferences appears
to be directed at vaccine development and novel agents.
Vaccines
The recognition that peptic ulcer is caused by an infectious agent suggests that the
disease may be prevented by vaccination [44]. Preliminary experiments in animals were
reported by Czinn et al. [45]. Oral immunization ofgerm-free mice with sonicated H.felis
plus cholera toxin resulted in elevated serum, gastric and intestinal anti-H. felis antibody.
70 percent of the immunized animals were subsequently protected from acute infection.
More recently mice have been immunized against H.felis infection by vaccines from dis-
rupted cells ofH. pylori or H. pylori urease preparations [46, 47]. Results of recent early
clinical trials with a recombinant urease vaccine in healthy volunteers have been encour-
aging [48].Williamson et al.: Treatmentsfor Helicobacterpylori infection
Virulence and pathogenicity factors of H. pylori may be suitable antigen candidates
for the development ofa vaccine. Major consideration is being given to the urease and fla-
gellae (two subunits, FlaA and FlaB) although the membranous sheath around the flagel-
la may prevent the FlaA protein being useful as a vaccine. Identification ofthe ulcerogenic
Type I strain of H. pylori suggests the possibility that vaccine development may be tar-
geted only toward those bacteria responsible for severe disease. Thus mice were immu-
nised with antigens peculiar to Type I bacteria and subsequently exposed to cytotoxic
strains. Immunization with purified VacA protected mice from infection with a Type I
strain of H. pylori but not from infection with Type II strains [49]. At present only one
gene (hpaA) coding for an adhesion subunit protein has been characterized and cloned
[50]. The future development ofvaccines to prevent adhesion ofH. pylori to mucosal cells
will rely on identification of the genes for other proteins mediating adhesion ofthe bacte-
ria.
Although most research with vaccines has focused on the "classical" prophylactic
approach, recent publications have shown that vaccines may have a "therapeutic" effect in
actually eradicating pre-existing infection with H. pylori [51-53]. A majorchallenge in the
perceived race to get a good vaccine for mucosal immunity is obtaining a safe and effec-
tive adjuvant, and a genetically detoxified E. coli enterotoxin may provide this [54].
Research is also continuing into antigen-coated particles, attenuated Vibrio cholerae,
Salmonella typhi and Shigella dysenteriae, as well as commensal bacteria, being devel-
oped as live vaccines.
Anti-adhesive agents
Oligosaccharide components of membrane glycoproteins and glycolipids act as bac-
terial adhesion ligands for H. pylori on epithelial cells. Soluble oligosaccharides mimick-
ing these epithelial ligands may disrupt bacterial attachment. The oligosaccharide, NE-
0080, detached bound bacteria from epithelial monolayers and, in gnotobiotic piglets
infected with pig-adapted H. pylori, reduced colonization in the majority of treated ani-
mals, and this agent is currently undergoing clinical investigation [55]. Similarly, fucosy-
lated glycosides inhibit adherence ofbacteria to mucosal surfaces. Compounds containing
a terminal L-fucose inhibited H. pylori binding to human gastric tissue in an in situ adher-
ence assay. Moreover, bismuth, in addition to its bactericidal properties, may influence
bacterial adhesion in vitro [56-59] and in vivo [60]. Lectins are also capable of prevent-
ing binding of H. pylori to colostral IgA [61]. Binding was inhibited by those with sialic
acid residues whereas non-sialylated carbohydrates had no effect.
Novel agents
In addition to on-going clinical trials of broad-spectrum antibiotics, generally com-
bined with acid-suppression, several companies have reported an interest in some novel
agents. Thus, agents such as an antimicrobial, cationic peptide used as a food additive
(nisin) from AMBI [62], a nitrothiazole (nitazoxanide) from Romark Laboratories [63],
and a lipid preparation (HelicoreTM) from NovaVax, Inc. [64], are all undergoing early
clinical trials.
Prevention oftransmission ofinfection
The mode or modes of transmission of H. pylori are still uncertain. Socio-economic
status has repeatedly been shown in many countries to have a strong inverse relationship
with H. pylori infection; family size, and hence overcrowding, the sharing of a bedroom
and of a bed being the key factors [65]. Thus reduced transmission may be achieved by
general improvement in living standards.
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Endoscopes are highly contaminated after use in H. pylori-positive patients.
Inadequate cleaning procedures in the past may therefore have led to iatrogenic transmis-
sion [66]. Guidelines now recommend extensive manual cleaning of all parts of an endo-
scope and submersion in glutaraldehyde for at least two minutes.
Hostfactors
Although the precise aetiology of gastric and duodenal ulceration is not established, a
number of risk factors are associated with the development of peptic ulcer disease in the
majority ofpatients. For example, these include excess gastric acid secretion, genetic pre-
disposition, cigarette smoking, and concomitant disease (hepatic cirrhosis, chronic pul-
monary failure, chronic renal failure). The interrelationship between such factors and H.
pylori infection in the pathogenesis ofpeptic ulceration has received little attention. It has
been suggested that all strains of H. pylori have the ability to induce ulceration if other
conditions are met, and a research priority should be the identification of those host fac-
tors which allow changes in the mucosal environment caused by colonization with any
strain of H. pylori to initiate duodenal ulceration [67].
Dietaryfactors
The influence of diet on the development of peptic ulceration has been recognised
[68] and may provide clues for future therapies. Observations that gastric bacterial metab-
olism may be inhibited by long-chain fatty acids [69-72] led to experiments showing that
two common dietary polyunsaturated fatty acids (o-3 linolenic acid and linoleic acid) dis-
rupted the cell membrane ofH. pylori, leading to lysis [73]. There has also been a report
thatH. pylori was cleared in six ofeightpatients who received two months' treatment with
apolyunsaturated fatty acid supplement (2 g linoleic/linolenic acid), although the mode of
action was unclear [74].
Medium-chain monoacylglycerol esters are bactericidal for H. pylori and H. felis in
vitro, and for the latter, also in vivo [75]. The mechanism of antibacterial activity is
unknown but disruption of cell membrane permeability and inhibition of amino acid
uptake have been suggested [76, 77].
Pasteurised and skimmed milk inhibited H. pylori following acidification with
hydrochloric acid to pH less than 5.5, or after digestion with trypsin [78]. The acid-
released inhibitor is unknown, whereas the trypsin-released inhibitor is derived from alpha
and kappa fractions of caseins. Lactoferrin, a glycoprotein found in mammalian milk, is
also able to inhibit the growth ofH. pylori [79].
Lactic acid-producing bacteria form substances that have bactericidal activities
against H. pylori [80], and it was shown in a recent randomized, double-blind clinical
study, that a whey-based Lactobacillus acidophilus culture supernatant (4 x 50 ml/day]
suppressed the growth ofH. pylori in 20 volunteers [81].
Other natural dietary constituents reported to possess anti-H. pyloriproperties in vitro
include extract ofblack and green tea [82], varieties ofChinese herbal medicines [83], and
Manuka honey [84].
Urease inhibition/carbonate removal
Although urease is essential for colonization, inhibition of its activity, by the potent
agent flurofamide, did not cause eradication of H. mustelae in an animal model [85].
Although benzimidazole proton pump inhibitors reduce urease activity in cell extracts and
in intact H. pylori [86], their effect on growth of H. pylori may be independent of the
inhibitory action ofthese agents against urease [87].
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Compounds removing bicarbonate, ammonium ions or urea from the gastric milieu
may eliminate the protective micro-environment from H. pylori thus rendering it suscep-
tible to the antibacterial properties ofgastric acid. Substances investigated include dibasic
magnesium compounds, dialdehyde polysaccharides, calcium and magnesium salts and
zeolites. Combined ammonia and bicarbonate scavengers were particularly effective when
used concomitantly.
"Topical" therapy
A novel approach to eradicate H. pylori by high luminal concentrations ofantibiotics
has been reported from Japan [88]. Using this technique, a concentrated solution of sodi-
um bicarbonate containing a proteolytic agent to dissolve gastric mucus, and a bacterici-
dal cocktail of bismuth subnitrate, amoxycillin and metronidazole was instilled into the
stomach via a nasal tube, after pre-treatment with lansoprazole and the proteolytic agent.
Importantly, leakage of the solution was prevented by a balloon catheter inflated in the
duodenum. The solution was kept in the stomach for one hour and the position of the
patient changed every 15 min to expose the entire mucosa, and the solution was removed
by suction after the procedure. H. pylori infection was reported to be eradicated in 24/25
(96 percent) ofpatients, with the one failure due to balloon failure!
Novel drug formulations may offer greater gastric retention times thus increasing
exposure of H. pylori to an antibiotic. Such a formulation comprising a benzene-based
antimicrobial, muco-adherent cellulose derivative and a chelating agent has been
described. Suggestions of mucoadhesive agents, floating devices, mucolytic agents to
enhance drug penetration, acid-stable antibiotics, and agents which markedly slow gastric
emptying to prolong gastric residence time for an antibiotic have all been proposed.
Colostral antibodies
Antigen-specific antibodies from cow's milk may target a broad range of pathogens
in the gastrointestinal tract [89]. Orally administered bovine immunoglobulins with activ-
ity against highly purified H. pylori antigens may eradicate the organism [90]. The effica-
cy of an immunoglobin concentrate derived from mammary gland secretions of animals
immunised with H. pylori has also been assessed in gnotobiotic piglets. There was a
reduction or elimination of H. pylori-induced pathological changes and bacterial colo-
nization of various gastric epithelial regions.
WHAT IS NEW AND CURRENTLY AVAILABLE IN ERADICATION THERAPY
Ranitidine bismuth citrate (RBC)b is the first and only compound specifically intro-
duced for the eradication ofH. pylori. It is a novel compound with unique physicochem-
ical properties. For example, when compared with bismuth citrate it is some 50,000-fold
more soluble, inhibits human pepsin isoenzymes in vitro, and is more effective at inhibit-
ing the growth of H. pylori both in vitro and in vivo [91]. Moreover, RBC kills H. pylori
rather thanjust having a bacteriostatic effect. This rate ofkilling is significantly increased
in a synergistic manner when antibiotics such as clarithromycin or metronidazole are
added to low concentrations of RBC. Clinical studies have demonstrated that this may
contribute to efficacy, Peterson et al. [92] reported 82 percent eradication with two weeks
dual therapy ofRBC 400 mg twice daily plus clarithromycin 500 mg three times each day,
whereas RBC alone gave no eradication, and clarithromycin alone eradicated the organ-
ism in only 36 percent of patients treated. A simpler dosing regimen of both agents has
been shown to eradicate H. pylori in 96 percent of patients after two weeks therapy of
RBC 400 mg twice daily plus clarithromycin 500 mg twice daily [93]. Moreover, a one
week therapy of RBC twice daily plus two antibiotics twice daily has also been shown to
be highly effective [94, 95].
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Apart from RBC, it is unlikely that there will be any new medicines for the eradica-
tion of H. pylori over the next few years due to the long lead time for drug development
and approval. Optimization ofcurrent therapeutic approaches using two week dual or one
week triple therapy regimens involving proton pump inhibitors or RBC are therefore like-
ly to feature in the evolution oferadication therapy in the immediate future.
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